In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Beware Bad Actors And Avoid A Cyber Securing Shock

How Healthcare Players Can Lower The Risk Of Making A Cyber Insurance Claim

Executive Summary

Medtech and pharma and businesses can take steps to avoid having to claim on their cyber insurance policies, says Edward Machin of law firm Ropes & Gray.

You may also be interested in...



Vascepa Infringement Dismissal ‘Resulted In Multiple Errors,’ Amarin Argues

Amarin is digging deep to take Hikma back before a US district court in its induced infringement case against the generics manufacturer.

Generic Pylera Leads Charge As Endo Aims To Fix Up Floundering Business

Endo has launched the first generic version of Allergan’s H. pylori treatment Pylera and plans to launch around 10 products from its sterile injectables and generics businesses this year.

BrainStorm’s ALS Treatment NurOwn, Filed Over Protest, Will Get US FDA Panel Review

A November 2022 refuse-to-file letter cited clinical and statistical issues for the stem cell therapy, which failed its Phase III clinical efficacy endpoint. However, BrainStorm has consistently asserted that NurOwn demonstrated benefit in patients with less advanced disease at baseline, and it is encouraged by regulatory flexibility FDA recently has shown for the neurodegenerative disease.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

IV147669

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel